Demant A/S Unsponsored ADR (OTCMKTS:WILYY) Sees Significant Increase in Short Interest

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) was the target of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 2,028 shares, an increase of 2,231.0% from the May 14th total of 87 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 752 shares, the days-to-cover ratio is presently 2.7 days.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised shares of Demant A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 18th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy”.

Demant A/S Stock Performance

Shares of WILYY remained flat at $20.05 during midday trading on Wednesday. The stock had a trading volume of 318 shares, compared to its average volume of 231. The stock’s 50 day moving average is $17.19 and its 200-day moving average is $16.12. Demant A/S has a 12-month low of $13.45 and a 12-month high of $21.93. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.